Company: HVIIR
Filing Date: 2025-12-23
Form Type: S-4
Source: 0001493152-25-029121
Chunk: 30

Company: Hennessy Capital Investment Corp. VII
Filing Date: 2025-12-23
Form: S-4
Chunk 30
---
.” A copy of the Business Combination Agreement is attached to this proxy statement/prospectus as Annex A.

On the Closing Date prior to Closing, (a) each then issued and outstanding HVII Class B Ordinary Share will convert (the “Sponsor Share Conversion”) automatically, on a one-for-one basis, into one HVII Class A Ordinary Share; (b) immediately after the Sponsor Share Conversion, HVII will transfer by way of continuation and deregistration to and domesticate as a Delaware corporation (such continuation and domestication, the “Domestication”); and (c) in connection with, and after giving effect to, the Domestication, (i) each then issued and outstanding HVII Class A Ordinary Share will convert automatically, on a one-for-one basis, into one share of New ONE Nuclear Common Stock, (ii) each then issued and outstanding HVII Right will convert automatically into a right to acquire one-twelfth (1/12) of one share of New ONE Nuclear Common Stock at Closing (each a “Domesticated HVII Right”), and (iii) each then issued and outstanding unit of HVII will be cancelled, and one share of New ONE Nuclear Common Stock and one Domesticated HVII Right will be issued in respect thereof. See the section of this proxy statement/prospectus entitled “The Business Combination”for further information on the consideration being paid to the ONE Nuclear Members.

HVII Shareholders are being asked to consider and vote upon the Business Combination Proposal to approve and adopt of the Business Combination Agreement, among the other Proposals.

HVII Units, HVII Class A Ordinary Shares, and HVII Public Rights are currently listed on the Nasdaq Global Market under the symbols “HVIIU,” “HVII,” and “HVIIR,” respectively. Shares of New ONE Nuclear Common Stock are expected to trade on the Nasdaq under the ticker symbol “ONEN” following the Closing. At the Closing, each twelve (12) Domesticated HVII Rights will convert into one share of New ONE Nuclear Common Stock, and therefore there will be no Nasdaq listing of the Domesticated HVII Rights following the consummation of the Business Combination.

This proxy statement/prospectus and its annexes contain important information about the proposed Business Combination and the proposals to be acted upon at the HVII Shareholders’ Meeting. You should read this proxy statement/prospectus and its annexes carefully and in their entirety. This document also constitutes a prospectus of New ONE Nuclear with respect to the shares of